Novavax (NVAX) says its respiratory syncytial virus vaccine met objectives in a Phase II...
Novavax (NVAX) says its respiratory syncytial virus vaccine met objectives in a Phase II clinical trial. The company says the drug was well-tolerated and there "were no clinically important differences in systemic adverse events between placebo and active vaccine recipients." Shares +7% AH.
From other sites
at CNBC.com (Jan 15, 2015)
at CNBC.com (Jun 6, 2014)
at CNBC.com (Apr 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs